Prof Keating speaks with ecancertv at ASH 2016 about presentations from Dr Terry Fry and Dr Jeff Lancet, in which twists on existing leukaemia therapies gave new insight on disease treatment

For more from Prof Jeff Lancet on CPX-351, a liposomal injection of daunorubicin and cytarabin in a 5:1 ratio, you can watch his interview with ecancer here.

For more from Dr Nirali Shah on CAR T cells targetting CD22 for patients relapsing after CD19 therapy, you can see her interview with ecancer here.

ecancer's filming at ASH 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.